AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO Stock Up 5.0 %
Shares of AVRO opened at $1.06 on Thursday. AVROBIO has a twelve month low of $0.74 and a twelve month high of $6.88. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 0.10. The company has a 50 day moving average of $0.97 and a 200-day moving average of $1.19.
AVROBIO (NASDAQ:AVRO - Get Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). On average, sell-side analysts predict that AVROBIO will post -2.14 EPS for the current year.
Wall Street Analyst Weigh In
Several research analysts have issued reports on AVRO shares. Barclays cut their price objective on AVROBIO from $6.00 to $4.00 in a research report on Wednesday, May 11th. Wedbush dropped their price target on shares of AVROBIO from $14.00 to $4.00 in a research note on Wednesday, May 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $5.29.